COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Income Growth Analysis including revenue, gross profit, operating profit, net profit, EPS, and other financial metrics. Compare income growth against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.

Revenue Growth

5.02%

Decreased from previous period

Growth of 5.02% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

4.41%

Decreased from previous period

Cost growth of 4.41% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

7.85%

Increased from previous period

Growth of 7.85% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

2.70%

Increased from previous period

Margin change of 2.70% versus flat Healthcare margins. Walter Schloss would verify quality.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

-100.00%

G&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency gains.

Selling & Marketing Expenses Growth

-100.00%

Marketing expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive implications.

Other Expenses Growth

-13.38%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

2.50%

Decreased from previous period

Operating expenses change of 2.50% versus flat Healthcare costs. Walter Schloss would verify control.

Total Costs & Expenses Growth

4.12%

Decreased from previous period

Total costs change of 4.12% versus flat Healthcare costs. Walter Schloss would verify control.

Interest Expense Growth

-7.69%

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

-13.71%

Decreased from previous period

D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.

EBITDA Growth

14.12%

Increased from previous period

EBITDA growth while Healthcare declines. Peter Lynch would examine advantages.

EBITDA Margin Growth

8.67%

Increased from previous period

Margin change of 8.67% versus flat Healthcare. Walter Schloss would verify quality.

Operating Income Growth

30.87%

Increased from previous period

Income change of 30.87% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

24.62%

Increased from previous period

Margin change of 24.62% versus flat Healthcare. Walter Schloss would verify quality.

Other Income/Expenses Growth

-58.74%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

14.19%

Increased from previous period

Income change of 14.19% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

8.73%

Increased from previous period

Margin change of 8.73% versus flat Healthcare. Walter Schloss would verify quality.

Income Tax Expense Growth

24.10%

Increased from previous period

Tax expense change of 24.10% versus flat Healthcare. Walter Schloss would verify strategy.

Net Income Growth

8.00%

Increased from previous period

Income change of 8.00% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

2.84%

Increased from previous period

Margin change of 2.84% versus flat Healthcare. Walter Schloss would verify quality.

EPS Growth

8.01%

Increased from previous period

EPS change of 8.01% versus flat Healthcare. Walter Schloss would verify quality.

Diluted EPS Growth

8.01%

Increased from previous period

Diluted EPS change of 8.01% versus flat Healthcare. Walter Schloss would verify quality.

Share Count Growth (Basic)

-0.00%

Decreased from previous period

Share count reduction while Healthcare median is 0.00%. Seth Klarman would investigate strategy.

Share Count Growth (Diluted)

-0.00%

Decreased from previous period

Diluted share reduction while Healthcare median is 0.00%. Seth Klarman would investigate strategy.

Select Chart Metric:

3349.T Income Growth Analysis

Compare against a Competitor

None 3391.T 3141.T 3088.T 2127.T 9843.T

Revenue Growth

5.02%

Decreased from previous period

Growth of 5.02% versus flat Healthcare revenue. Walter Schloss would verify growth quality.

Cost of Revenue Growth

4.41%

Decreased from previous period

Cost growth of 4.41% versus flat Healthcare costs. Walter Schloss would verify cost control.

Gross Profit Growth

7.85%

Increased from previous period

Growth of 7.85% versus flat Healthcare gross profit. Walter Schloss would verify quality.

Gross Margin Ratio Growth

2.70%

Increased from previous period

Margin change of 2.70% versus flat Healthcare margins. Walter Schloss would verify quality.

R&D Expenses Growth

No Data

No Data available this quarter, please select a different quarter.

G&A Expenses Growth

-100.00%

G&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency gains.

Selling & Marketing Expenses Growth

-100.00%

Marketing expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive implications.

Other Expenses Growth

-13.38%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Operating Expenses Growth

2.50%

Decreased from previous period

Operating expenses change of 2.50% versus flat Healthcare costs. Walter Schloss would verify control.

Total Costs & Expenses Growth

4.12%

Decreased from previous period

Total costs change of 4.12% versus flat Healthcare costs. Walter Schloss would verify control.

Interest Expense Growth

-7.69%

Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Depreciation & Amortization Growth

-13.71%

Decreased from previous period

D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.

EBITDA Growth

14.12%

Increased from previous period

EBITDA growth while Healthcare declines. Peter Lynch would examine advantages.

EBITDA Margin Growth

8.67%

Increased from previous period

Margin change of 8.67% versus flat Healthcare. Walter Schloss would verify quality.

Operating Income Growth

30.87%

Increased from previous period

Income change of 30.87% versus flat Healthcare. Walter Schloss would verify quality.

Operating Margin Growth

24.62%

Increased from previous period

Margin change of 24.62% versus flat Healthcare. Walter Schloss would verify quality.

Other Income/Expenses Growth

-58.74%

Decreased from previous period

Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.

Pre-Tax Income Growth

14.19%

Increased from previous period

Income change of 14.19% versus flat Healthcare. Walter Schloss would verify quality.

Pre-Tax Margin Growth

8.73%

Increased from previous period

Margin change of 8.73% versus flat Healthcare. Walter Schloss would verify quality.

Income Tax Expense Growth

24.10%

Increased from previous period

Tax expense change of 24.10% versus flat Healthcare. Walter Schloss would verify strategy.

Net Income Growth

8.00%

Increased from previous period

Income change of 8.00% versus flat Healthcare. Walter Schloss would verify quality.

Net Margin Growth

2.84%

Increased from previous period

Margin change of 2.84% versus flat Healthcare. Walter Schloss would verify quality.

EPS Growth

8.01%

Increased from previous period

EPS change of 8.01% versus flat Healthcare. Walter Schloss would verify quality.

Diluted EPS Growth

8.01%

Increased from previous period

Diluted EPS change of 8.01% versus flat Healthcare. Walter Schloss would verify quality.

Share Count Growth (Basic)

-0.00%

Decreased from previous period

Share count reduction while Healthcare median is 0.00%. Seth Klarman would investigate strategy.

Share Count Growth (Diluted)

-0.00%

Decreased from previous period

Diluted share reduction while Healthcare median is 0.00%. Seth Klarman would investigate strategy.

Select Chart Metric: